CapStone Initiates Coverage on Talecris Biotherapeutics (TLCR) with a Buy; Unique Play in Pure Plasma Therapeutics
Tweet Send to a Friend
CapStone initiates coverage on Talecris Biotherapeutics (Nasdaq: TLCR) with a Buy. Price target $28.
CapStone analyst says, "Through its recent ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
CapStone analyst says, "Through its recent ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
